ArticleCancers2025

A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of

Lucia Motta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.